{
  "id": "a8bf5ecb03e02740",
  "title": "Neurocrine Biosciences Presents Head - to - Head INGREZZA\u00ae ( valbenazine ) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR",
  "description": "20260115T134500Z",
  "content": "",
  "source": "prnewswire.com",
  "source_url": "https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-head-to-head-ingrezza-valbenazine-capsules-data-demonstrating-higher-vmat2-target-occupancy-compared-to-austedo-xr-302661800.html",
  "published_at": "20260115T134500Z",
  "fetched_at": "2026-01-16T00:24:08.160649+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-head-to-head-ingrezza-valbenazine-capsules-data-demonstrating-higher-vmat2-target-occupancy-compared-to-austedo-xr-302661800.html",
    "url_mobile": "",
    "title": "Neurocrine Biosciences Presents Head - to - Head INGREZZA\u00ae ( valbenazine ) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR",
    "seendate": "20260115T134500Z",
    "socialimage": "",
    "domain": "prnewswire.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}